Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVRNA009 as Heterologous Booster in CoronaVac-Vaccinated Adults
NCT05428592Phase 3Unknown
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of LVRNA009 in coronavirus disease 2019 (COVID-19), sponsored by AIM Vaccine Co., Ltd.. Status: unknown.
02
Drugs
LVRNA009
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05428592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05428592.